Datopotamab deruxtecan
CAS No. 2238831-60-0
Datopotamab deruxtecan ( —— )
产品货号. M35147 CAS No. 2238831-60-0
Datopotamab deruxtecan (DS-1062; Dato-DXd) 是一种滋养层细胞表面抗原 2 (TROP2) 导向的抗体活性分子偶联物 (ADC)。Datopotamab deruxtecan 具有强大的抗肿瘤活性。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥20140 | 有现货 |
|
| 10MG | ¥27265 | 有现货 |
|
| 25MG | ¥39618 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Datopotamab deruxtecan
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Datopotamab deruxtecan (DS-1062; Dato-DXd) 是一种滋养层细胞表面抗原 2 (TROP2) 导向的抗体活性分子偶联物 (ADC)。Datopotamab deruxtecan 具有强大的抗肿瘤活性。
-
产品描述Datopotamab deruxtecan (DS-1062; Dato-DXd) is a trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC). Datopotamab deruxtecan has a potent antitumor activity.
-
体外实验Datopotamab deruxtecan (Dato-DXd; 100 μg/mL) binds specifically to TROP2 and was internalized into tumor cells followed by intracellular trafficking to lysosome and Deruxtecan release, which induced DNA damage and apoptosis in TROP2-expressing tumor cells in vitro.
-
体内实验Datopotamab deruxtecan (Dato-DXd; 6 mg/kg) shows potent antitumor activity with tumor regression in several TROP2-expressing xenograft tumors including NSCLC patient-derived xenograft (PDX) models. Safety profiles of Datopotamab deruxtecan in rats and cynomolgus monkeys are acceptable.
-
同义词——
-
通路Cell Cycle/DNA Damage
-
靶点Topoisomerase
-
受体Topoisomerase | Antibody-Drug Conjugates (ADCs)
-
研究领域——
-
适应症——
化学信息
-
CAS Number2238831-60-0
-
分子量
-
分子式——
-
纯度>98% (HPLC)
-
溶解度——
-
SMILES——
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Daisuke Okajima, et al. Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells. Mol Cancer Ther. 2021 Aug 19.?
021-51111890
购物车()
sales@molnova.cn

